Seth M. Pollack, MD, discussed how the ECOG-ACRIN EA7222 trial could establish doxorubicin/pembrolizumab as the new frontline standard for undifferentiated pleomorphic sarcoma.
Seth M. Pollack, MD
Advertisement
Articles by Seth M. Pollack, MD
Seth M. Pollack, MD, discusses new strategies for converting immune-cold tumors, including the role of TLR4 agonists and IL-12–producing viral agents.
Advertisement
Latest Updated Articles
Redefining Frontline Therapy in Undifferentiated Pleomorphic SarcomaFebruary 20th 2026
Advertisement
Advertisement
Trending on CancerNetwork
1
Low-Dose CT Screening Reduces Lung Cancer–Specific Mortality
2
FDA Approves Companion Diagnostic for Pembrolizumab in Esophageal/GEJ Carcinoma
3
Durvalumab/SBRT May Limit Tumor Progression in Early-Stage NSCLC
4
Frontline IO-Combos, Next-Generation ADCs: Evolutions in Endometrial Cancer
5